A new era in the management of psoriasis? The biologics: facts and controversies

Clin Dermatol. 2010 Jan-Feb;28(1):81-7. doi: 10.1016/j.clindermatol.2009.03.002.

Abstract

During the last 30 years, the tremendous progress in our knowledge of the pathogenesis of psoriasis has led to the development of new agents, the so-called biologics, that have revolutionized the management of severe psoriasis. Dermatologists and patients see this emerging therapy as a new perspective in the state of the art in managing moderate to severe psoriasis. After a few years of use in daily practice, we may begin to analyze the power of the currently available biologic agents in the management of severe psoriasis from the perspective of facts.

Publication types

  • Review

MeSH terms

  • Alefacept
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Biological Products / economics*
  • Biological Products / therapeutic use*
  • Cost-Benefit Analysis
  • Dermatologic Agents / economics*
  • Dermatologic Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Etanercept
  • Evidence-Based Medicine
  • Humans
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Psoriasis / drug therapy
  • Psoriasis / economics*
  • Psoriasis / therapy*
  • Randomized Controlled Trials as Topic
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use
  • Ultraviolet Rays

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Dermatologic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Recombinant Fusion Proteins
  • Infliximab
  • Alefacept
  • Etanercept
  • efalizumab